Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
Alternative endpoints to the 5‑year overall survival and locoregional control for nasopharyngeal carcinoma: A retrospective analysis of 2,450 patients
Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up - ESMO Open
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
Efficacy Results | Myelofibrosis Clinical Trials | Jakafi HCP
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
View Image
5-year overall survival almost doubled with pembrolizumab for metastatic NSCLC patients with a PD-L1 TPS ≥ 50% and without EGFR/ALK alterations - BJMO
A nomogram to predict overall survival for biliary tract cancer | CMAR
![PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cbf64e0a2a5bc6572dc331e433efae660922309/5-Table2-1.png "PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar")
PDF] Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study | Semantic Scholar
OA08.03 The 5-year Survival Rate of Postoperative Non-small Cell Lung Cancer Patients with Two Different Follow-up Patterns - Journal of Thoracic Oncology
Long-term survival and stage I breast cancer subtypes - ScienceDirect
VENCLEXTA® (venetoclax tablets) | Additional Follow-up Data for CLL/SLL
5-year Overall Survival Rates by Stage at Presentation | Download Scientific Diagram
Overall survival curve by treatment method. The 5-year overall survival... | Download Scientific Diagram
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy | In Vivo
Five-year survival analysis of surgically resected gastric cancer cases in Japan: a retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001–2007) | SpringerLink
Cancers | Free Full-Text | Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer | HTML
5-year overall survival rates of Different Tumor Stages. After Log-rank... | Download Scientific Diagram
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database | BMC Cancer | Full Text
Study shows survival benefits of smoking cessation after lung cancer diagnosis
![PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,](https://og.oa.mg/Long-Term%20(5%20Year)%20Overall%20Survival%20in%20Zuma-1,%20the%20Pivotal%20Study%20of%20Axicabtagene%20Ciloleucel%20(Axi-Cel)%20in%20Patients%20with%20Refractory%20Large%20B-Cell%20Lymphoma%20(LBCL).png?author=%20Caron%20A.%20Jacobson,%20Frederick%20L.%20Locke,%20Armin%20Ghobadi,%20David%20B.%20Miklos,%20Lazaros%20J.%20Lekakis,%20Olalekan%20O.%20Oluwole,%20Yi%20Lin,%20Brian%20T.%20Hill,%20John%20M.%20Timmerman,%20Abhinav%20Deol,%20Patrick%20M.%20Reagan,%20Patrick%20Stiff,%20Ian%20W.%20Flinn,%20Umar%20Farooq,%20Andre%20H.%20Goy,%20Javier%20Mu%C3%B1oz,%20Tanya%20Siddiqi,%20Rhine%20R%20Shen,%20Adrian%20Bot,%20Jinghui%20Dong,%20Kanwarjit%20Singh,%20Clare%20Spooner,%20Roshan%20Karalliyadda,%20Jenny%20J.%20Kim,%20Yan%20Zheng,%20Sattva%20S.%20Neelapu "PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,")
PDF] Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL) by Caron A. Jacobson, Frederick L. Locke, Armin Ghobadi,
